Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by Privium Fund Management B.V.

Privium Fund Management B.V. grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 111.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,709 shares of the company’s stock after purchasing an additional 31,000 shares during the period. Privium Fund Management B.V. owned approximately 0.06% of Intellia Therapeutics worth $417,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Intellia Therapeutics by 51.7% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 19,726 shares of the company’s stock valued at $140,000 after purchasing an additional 6,722 shares in the last quarter. D.A. Davidson & CO. raised its holdings in shares of Intellia Therapeutics by 76.2% during the 1st quarter. D.A. Davidson & CO. now owns 26,020 shares of the company’s stock valued at $185,000 after buying an additional 11,250 shares during the period. California State Teachers Retirement System raised its holdings in shares of Intellia Therapeutics by 4.1% during the 4th quarter. California State Teachers Retirement System now owns 90,638 shares of the company’s stock valued at $1,057,000 after buying an additional 3,596 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Intellia Therapeutics during the 4th quarter valued at about $4,793,000. Finally, Baker BROS. Advisors LP purchased a new stake in shares of Intellia Therapeutics during the 4th quarter valued at about $7,510,000. 88.77% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

NTLA has been the topic of several analyst reports. Canaccord Genuity Group dropped their target price on Intellia Therapeutics from $74.00 to $54.00 and set a “buy” rating on the stock in a report on Tuesday, June 3rd. Wedbush reiterated a “neutral” rating and set a $7.00 target price on shares of Intellia Therapeutics in a report on Monday, June 16th. Citigroup dropped their target price on Intellia Therapeutics from $14.00 to $10.00 and set a “neutral” rating on the stock in a report on Friday, May 9th. Chardan Capital reiterated a “buy” rating and set a $68.00 target price on shares of Intellia Therapeutics in a report on Friday, May 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Intellia Therapeutics in a report on Monday, June 16th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.37.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock opened at $11.49 on Friday. The company has a market cap of $1.19 billion, a PE ratio of -2.20 and a beta of 2.31. The company has a fifty day moving average price of $10.25 and a two-hundred day moving average price of $9.44. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $24.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.16. The firm had revenue of $16.63 million during the quarter, compared to the consensus estimate of $11.39 million. Intellia Therapeutics had a negative net margin of 1,154.10% and a negative return on equity of 56.06%. The firm’s revenue was down 42.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.12) earnings per share. Equities research analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Insider Buying and Selling

In other Intellia Therapeutics news, EVP Edward J. Dulac III sold 7,462 shares of Intellia Therapeutics stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total value of $104,617.24. Following the completion of the transaction, the executive vice president owned 106,062 shares of the company’s stock, valued at $1,486,989.24. The trade was a 6.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders have sold a total of 12,534 shares of company stock valued at $153,837 over the last three months. Insiders own 3.10% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.